Ovarian Cancer – Unmet Need – Detailed, Expanded Analysis (US/EU)
The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca, have revolutionized the therapeutic landscape of platinum-sensitive ovarian cancer, where platinum-based regimens used to be the standard of care. Although substantial improvements have been made with the FDA’s 2019 approval of Lynparza for first-line maintenance therapy in advanced ovarian cancer, opportunity exists to develop more effective therapies for platinum-sensitive disease, while optimal sequencing of these therapies remains an unmet need.
QUESTIONS ANSWERED
- What are the treatment drivers and goals in surveyed medical oncologists’ prescribing decisions? What are the hidden opportunities that developers could leverage?
- How do current therapies, such as the PARP inhibitors, perform on key clinical attributes for this patient population?
- What are the greatest areas of unmet need and most attractive opportunities for platinum-sensitive ovarian cancer?
- What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles?
PRODUCT DESCRIPTION
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 62 U.S. and 30 European medical oncologists fielded in June 2020
Key companies: AstraZeneca, GSK, Clovis Oncology
Key drugs: Lynparza, Zejula, Rubraca
Table of contents
- Ovarian Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU)
- Executive Summary
- Unmet Need - Platinum-Sensitive Ovarian Cancer - Executive Summary - September 2020
- Introduction
- Methodology
- Rationale for Treatment Drivers and Goals Selection
- Rationale for Drug Selection
- Regimens for Platinum-Sensitive Ovarian Cancer and Rationale for Drug Selection
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Medical Oncologists' Prescribing Decisions in Platinum-Sensitive Ovarian Cancer
- Importance of Efficacy Attributes to Prescribing Decisions in Platinum-Sensitive Ovarian Cancer: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Platinum-Sensitive Ovarian Cancer: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Platinum-Sensitive Ovarian Cancer: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Platinum-Sensitive Ovarian Cancer: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Platinum-Sensitive Ovarian Cancer: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Platinum-Sensitive Ovarian Cancer: Europe
- Importance of Nonclinical Factors to Prescribing Decisions in Platinum-Sensitive Ovarian Cancer: United States
- Importance of Nonclinical Factors to Prescribing Decisions in Platinum-Sensitive Ovarian Cancer: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Platinum-Sensitive Ovarian Cancer: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Platinum-Sensitive Ovarian Cancer: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer: United States
- Overall Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer: Europe
- Mean Overall Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer: United States and Europe
- Relative Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer Across Select Convenience of Administration Attributes: Europe
- Relative Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer Across Select Nonclinical Attributes: United States
- Relative Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer Across Select Nonclinical Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in Platinum-Sensitive Ovarian Cancer
- Surveyed Medical Oncologistsu2019 Satisfaction with the Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Medical Oncologistsu2019 Satisfaction with the Performance of Key Therapies for Platinum-Sensitive Ovarian Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Platinum-Sensitive Ovarian Cancer: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Platinum-Sensitive Ovarian Cancer: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Platinum-Sensitive Ovarian Cancer: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Platinum-Sensitive Ovarian Cancer: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Platinum-Sensitive Ovarian Cancer: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Platinum-Sensitive Ovarian Cancer: Europe
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Platinum-Sensitive Ovarian Cancer: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Platinum-Sensitive Ovarian Cancer: Europe
- Key Findings: Unmet Need in Platinum-Sensitive Ovarian Cancer and Related Indications
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Platinum-Sensitive Ovarian Cancer and Related Indications: United States
- Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Platinum-Sensitive Ovarian Cancer and Related Indications: Europe
- Opportunity Analysis
- Areas of Opportunity in the Platinum-Sensitive Ovarian Cancer Market and Emerging Therapy Insights
- Opportunity: A Novel Therapy Offering a Substantial Overall Survival Benefit
- Opportunity: A Novel Therapy with Improved Progression-Free Survival
- Opportunity: A Novel Therapy with a Better Safety and Tolerability Profile
- Areas of Opportunity in the Platinum-Sensitive Ovarian Cancer Market and Emerging Therapy Insights
- Target Product Profiles
- Assessing Drug Development Opportunities
- Target Product Profile Methodology
- Attributes and Attribute Levels
- Attribute Importance and Part-Worth Utilities
- First-Line Platinum-Sensitive Ovarian Cancer Target Product Profile: Attribute Importance
- Median Overall Survival (Months)
- Median Progression-Free Survival (Months)
- Objective Response Rate (% of Patients)
- Incidence of Grade 3/4 Hematological Toxicities (% of Patients)
- Incidence of Grade 3/4 Gastrointestinal Toxicities (% of Patients)
- Incidence of Grade 3/4 General Disorders (% of Patients)
- Price per 21-Day Cycle (Induction and/or Maintenance Therapy)
- Conjoint Analysis-Based Simulation of a Market Scenario
- First-Line Platinum-Sensitive Ovarian Cancer Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
- First-Line Platinum-Sensitive Ovarian Cancer Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
- First-Line Platinum-Sensitive Ovarian Cancer Market Simulation: Target Product Profiles Included in the Market Scenario
- Appendix
- Key Abbreviations
- Bibliography
- Executive Summary
Laura Vinuesa, D.V.M., M.Sc., is a senior business insights analyst on the Oncology team at Clarivate. She specializes in bladder cancer and head and neck cancers and in optimizing market access opportunities for new biomarker-targeted therapies in oncology. Previously, she was part of the Global Market Access Insights team, for whom she analyzed the healthcare systems and pharmaceutical markets of the EU5 and focused on evolving HTA demands, P&R processes, and stringent cost-containment strategies. She obtained her doctorate in veterinary medicine from Complutense University in Madrid and a master’s degree in clinical research and pharmaceutical medicine from EPHOS Business School in Madrid.